studies, as noted above, have unraveled novel cellular and molecular insights into the lithium’s effects on renal tubular cells in AKI and in NDI.

ACKNOWLEDGMENTS

The study was supported in part by grants from National Natural Science Foundation of China (81370791), National Basic Research Program of China 973 Program No. 2012CB517600, and the National Institutes of Health and Department of Veterans Administration.

DISCLOSURES

None.

REFERENCES

4. Kishore BK, Ecelbarger CM: Lithium: A versatile tool for understanding angiotensin inhibition, but this is only partially successful and it is imperative to determine the mechanisms leading to its development. Current antiproteinuric therapy relies mainly on renin-angiotensin inhibition, with ET-1 being the most relevant in kidney function. Therefore, selective blockade of ETAR with haptenic acid is an effective way to treat renal disease. J Am Soc Nephrol 25: 423–425, 2014.

Proteinuria is a major pathologic feature of a wide variety of progressive CKD. Even if it is accompanied by a normal GFR, proteinuria indicates significant kidney dysfunction and its presence has been incorporated into definitions for CKD. Because proteinuria is an independent risk factor for CKD, it is imperative to determine the mechanisms leading to its development. Current antiproteinuric therapy relies mainly on renin-angiotensin inhibition, but this is only partially successful and novel treatments are urgently needed.

In this issue of JASN, Buell et al. examine how endothelin-1 (ET-1) mediates podocyte injury/dysfunction. The endothelins are a family of vasoactive peptides with a variety of roles in human disease, with ET-1 being the most relevant in kidney pathology. ET-1 binds to two receptors, endothelin A and endothelin B receptors (ETAR and ETBR, respectively). In general, ETAR is responsible for vasoconstrictive and pathologic actions of ET-1, whereas ETBR governs protective vasodilatory functions. Therefore, selective blockade of ETAR with pharmacologic agents such as sitaxsentan and atrasentan has been explored as a renoprotective therapy, and positive results in reducing proteinuria were demonstrated in a variety of kidney diseases, including diabetic nephropathy.


Arrestin(g) Podocyte Injury with Endothelin Antagonism

Roderick J. Tan* and Youhua Liu†
Departments of *Medicine and †Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania


Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Youhua Liu, Department of Pathology, University of Pittsburgh School of Medicine, S-405 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15261. Email: liuy@upmc.edu

Copyright © 2014 by the American Society of Nephrology
ET-1 was previously shown to play a critical role in the development of metastatic ovarian cancer by promoting the formation of an ETAR/β-arrestin/Src kinase complex in an autocrine manner, which leads to stabilization and upregulation of β-catenin and Snail transcriptional regulators. Such actions resulted in an epithelial-to-mesenchymal transition of these cancer cells, increasing their invasive potential. These findings are relevant for proteinuric kidney disease because podocytes undergo a similar transition to a more motile phenotype in crescentic renal diseases. Drawing upon this comparison with tumor cell behavior, the authors examined the role of ET-1 in podocyte phenotypic changes. Utilizing in vitro podocyte cultures, they found that ET-1 does in fact induce an epithelial-to-mesenchymal transition—like event, with concomitant downregulation of the podocyte marker synaptopodin and upregulation of α-smooth muscle actin. These changes were associated with increased motility in a wound healing assay.

Turning to in vivo studies, the authors utilized the adriamycin nephropathy model in mice. This model recapitulates proteinuric renal disease, with features similar to human FSGS. The authors demonstrated a loss of Wilms tumor 1 positivity in glomeruli after adriamycin administration, and scanning electron microscopy revealed markedly abnormal foot processes and enlarged podocytes. Treatment with the ETAR inhibitor sitaxsentan ameliorated these morphologic changes.

These results are perhaps not unexpected considering the antiproteinuric effect of ETAR inhibition. The more interesting and novel finding in this study is the elucidation of the mechanism underlying this protection. It appears that, similar to ovarian cancer cells, ET-1–mediated podocyte injury involves the activation of a protein known as β-arrestin-1. The arrestins are ubiquitous proteins that participate in functions as diverse as G-protein signaling and endocytosis. They are also capable of acting as scaffold proteins that can gather various intracellular proteins into close proximity to initiate complex signaling pathways.

Buelli et al. have performed a careful interrogation of the ET-1–triggered signaling events and demonstrate that ET-1 ligation to its receptor in podocytes leads to induction of β-arrestin-1 and promotes the formation of a multicomponent complex containing β-arrestin-1, ETAR, and Src kinase. β-Arrestin-1 is also upregulated in hyperplastic lesions in samples from adriamycin-treated rodents and in human crescentic glomerular disease biopsies, suggesting clinical relevance for the activation of this signaling complex. Interestingly, assembly and activation of the ETAR/β-arrestin/Src complex results in the transactivation of the EGF receptor, which triggers downstream signaling that ultimately leads to the stabilization and increased activity of β-catenin.

β-Catenin is a key transcriptional regulator that is essential for normal kidney development, but its activity is largely silenced in adult kidneys. However, growing evidence implicates hyperactive β-catenin activity in the pathogenesis of a variety of kidney diseases. As a transcriptional regulator, β-catenin controls, directly or indirectly, the expression of a battery of downstream target genes such as Snail1, plasminogen activator inhibitor-1, and matrix metalloproteinase-7, as well as multiple components of the renin-angiotensin system, all of which are highly relevant to kidney injury. Earlier studies showed that β-catenin activity is upregulated specifically in glomerular podocytes in various proteinuric kidney diseases such as FSGS and diabetic nephropathy and that genetic ablation of β-catenin in a podocyte-specific fashion protects kidneys against the development of proteinuria after adriamycin injury. Therefore, the trimeric complex of ETAR/β-arrestin-1/Src identified in this study mechanistically links ET-1 to the activation of β-catenin, a central player in mediating podocyte dysfunction.

The findings in this report are significant for many reasons. First, Buelli et al. clearly demonstrate that ET-1 has profound effects on podocyte phenotype and morphology including foot process architecture, which is associated with proteinuria. Second, the data provide evidence that ETAR activation and β-arrestin-1/Src recruitment lead to increased β-catenin activity primarily through an ET-1–driven, Wnt-independent pathway. Recent data have implicated β-catenin stabilization through ligation of Wnt to frizzled receptors on the cell surface via the so-called canonical pathway. The identification of the novel ET-1–driven ETAR/β-arrestin/Src pathway suggests that multiple pathways can lead to β-catenin activation in podocytes. This important finding carries significant therapeutic implications.

This study does, however, have limitations. In spite of the evidence showing favorable effects of ETAR blockade on podocyte phenotype and intracellular signal transduction, this study was unable to demonstrate a significant effect on proteinuria, which is the ultimate goal of podocyte protection. In separate studies, we also could not improve proteinuria in adriamycin nephropathy when atrasentan was given either before or after the initiation of injury. These observations are in harmony with the fact that although ET-1 was induced at late time points, no significant change in ETAR expression was found in this model of podocyte injury and proteinuria.

The lack of effect of ETAR inhibition on proteinuria could suggest that adriamycin may cause proteinuria by a mechanism that is independent of ET-1 regulation, although the ETAR/β-arrestin complex is clearly involved in regulating other aspects of podocyte biology such as migration and crescentic formation. The authors point out that the pores that form in the glomerular barrier may not be affected by ETAR blockade. Of note, ETAR inhibitors have been successful in reducing proteinuria in diabetic nephropathy and other renal injuries in which there is increased intraglomerular pressures. However, there is evidence that adriamycin nephropathy is not characterized by these increased intraglomerular pressures, perhaps explaining the lack of efficacy of ETAR on proteinuria in this model. Furthermore, adriamycin nephropathy is often considered to be a model of human FSGS with characteristic features of podocyte depletion, but it is not
traditionally utilized to study crescentic glomerular disease which is the type of renal disease characterized by podocyte migration. In this regard, it would be interesting to examine ETAR blockade in the antiglomerular basement membrane model of kidney disease, which more closely mimics crescentic glomerular disease.

Taken together, the study by Buelli et al. has identified a signaling cascade that leads to impaired podocyte phenotype and function, thereby providing significant insights into our understanding of podocyte injury in proteinuric glomerular disease. The novel associations made between ET-1, ETAR, β-arrestin-1, EGF receptor, and β-catenin now provide a number of promising targets for therapeutic intervention and will require further study in the future.

DISCLOSURES
None.

REFERENCES


Cardiovascular Events after AKI: A New Dimension

Chi-yuan Hsu and Kathleen D. Liu
Division of Nephrology, University of California–San Francisco, San Francisco, California


doi: 10.1681/ASN.2013121276

The possibility that AKI is a risk factor for subsequent cardiovascular disease is an intriguing one. Several studies have shown that survivors of AKI are at increased risk of death and CKD. Because cardiovascular disease is the leading cause of death in many countries, it would be useful to understand whether there is increased risk of cardiovascular events after an episode of AKI. Therefore, prospective studies, such as the National Institutes of Health–National Institute of Diabetes and Digestive and Kidney Diseases-sponsored ASeessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury study, have specified a priori adjudicated cardiovascular events as outcomes of interest.1

Although CKD and ESRD are now well accepted risk factors for cardiovascular disease, little is known about the connection between AKI and cardiovascular events. There are several potential pathophysiological mechanisms by which AKI may directly contribute to increased risk of cardiovascular disease, independent of its impact on CKD progression. There are limited data (mostly from children2) that AKI survivors have higher levels of BP, consistent with animal models showing that postischemic rats develop salt-sensitive hypertension.3 As discussed by Wu et al., there is a growing literature linking AKI to abnormalities in mineral metabolism, especially elevations in levels of fibroblast growth factor-23,4,5 a novel biomarker that has garnered great interest recently as likely being directly cardiotoxic.6 Finally, AKI is associated with acute increases in inflammatory cytokine levels.7–9 As has been shown in other acute conditions characterized by inflammation (e.g., acute